Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
Xilio Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Xilio Therapeutics's total debt was $1.55M at Mar 31, 2023. For fiscal 2022 it was $3.17M, down 67.1% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.17M | -67.1% |
| FY2021 | Dec 31, 2021 | $9.63M | +29.9% |
| FY2020 | Dec 31, 2020 | $7.41M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2023 | Mar 31, 2023 | $1.55M | -80.7% |
| Q4 FY2022 | Dec 31, 2022 | $3.17M | -67.1% |
| Q3 FY2022 | Sep 30, 2022 | $4.78M | -50.1% |
| Q2 FY2022 | Jun 30, 2022 | $6.39M | -13.7% |
| Q1 FY2022 | Mar 31, 2022 | $8.01M | – |
| Q4 FY2021 | Dec 31, 2021 | $9.63M | – |
| Q3 FY2021 | Sep 30, 2021 | $9.58M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.41M | – |
See a number that looks wrong?